Targeting Apoptosis in Cancer

Curr Oncol Rep. 2022 Mar;24(3):273-284. doi: 10.1007/s11912-022-01199-y. Epub 2022 Feb 3.

Abstract

Purpose of review: Apoptosis is a major mechanism of cancer cell death. Thus, evasion of apoptosis results in therapy resistance. Here, we review apoptosis modulators in cancer and their recent developments, including MDM2 inhibitors and kinase inhibitors that can induce effective apoptosis.

Recent findings: Both extrinsic pathways (external stimuli through cell surface death receptor) and intrinsic pathways (mitochondrial-mediated regulation upon genotoxic stress) regulate the complex process of apoptosis through orchestration of various proteins such as members of the BCL-2 family. Dysregulation within these complex steps can result in evasion of apoptosis. However, via the combined evolution of medicinal chemistry and molecular biology, omics assays have led to innovative inducers of apoptosis and inhibitors of anti-apoptotic regulators. Many of these agents are now being tested in cancer patients in early-phase trials. We believe that despite a sluggish speed of development, apoptosis targeting holds promise as a relevant strategy in cancer therapeutics.

Keywords: Anti-cancer therapeutics; Apoptosis; BH3; Cancer; Extrinsic apoptosis pathway; Intrinsic apoptosis pathway.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Apoptosis
  • Humans
  • Mitochondria / metabolism
  • Neoplasms* / drug therapy
  • Neoplasms* / metabolism
  • Proto-Oncogene Proteins c-bcl-2

Substances

  • Antineoplastic Agents
  • Proto-Oncogene Proteins c-bcl-2